Coeptis Therapeutics, Inc. (COEP)
NASDAQ: COEP · IEX Real-Time Price · USD
1.58
+0.08 (5.33%)
Jan 27, 2023, 4:00 PM EST - Market closed
Income Statement (Annual)
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
| Year | 2021 | 2020 | 2019 |
|---|---|---|---|
| Revenue
|
0.08 | 0.03 | 0 |
| Revenue Growth (YoY)
|
143.82% | - | - |
| Cost of Revenue
|
0 | 0.96 | 0 |
| Gross Profit
|
0.08 | -0.93 | 0 |
| Selling, General & Admin
|
14.12 | 5.78 | 0 |
| Research & Development
|
0 | 0 | 0 |
| Operating Expenses
|
14.12 | 5.78 | 0 |
| Operating Income
|
-14.05 | -6.71 | -0 |
| Interest Expense / Income
|
0.19 | 0.15 | 0 |
| Other Expense / Income
|
-0.78 | 2.29 | - |
| Pretax Income
|
-13.45 | -9.16 | -0 |
| Net Income
|
-13.45 | -9.16 | -0 |
| Shares Outstanding (Basic)
|
32 | 18 | 2 |
| Shares Outstanding (Diluted)
|
32 | 18 | 2 |
| Shares Change
|
79.11% | 944.93% | - |
| EPS (Basic)
|
-0.42 | -0.51 | - |
| EPS (Diluted)
|
-0.42 | -0.51 | - |
| Free Cash Flow Per Share
|
-0.14 | -0.17 | -0.00 |
| Gross Margin
|
100.00% | -3034.54% | - |
| Operating Margin
|
-18727.91% | -21823.77% | - |
| Profit Margin
|
-17932.37% | -29765.89% | - |
| Free Cash Flow Margin
|
-5985.92% | -10195.12% | - |
| EBITDA
|
-12.81 | -8.68 | -0 |
| EBITDA Margin
|
-17086.31% | -28232.72% | - |
| Depreciation & Amortization
|
0.45 | 0.32 | 0 |
| EBIT
|
-13.26 | -9.01 | -0 |
| EBIT Margin
|
-17682.86% | -29284.14% | - |
Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).